Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wellington, FL
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wellington, FL
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated:  12/31/1969
Site: 3202
mi
from
Antwerp,
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
Status: Enrolling
Updated: 12/31/1969
Site: 3202
mi
from
Antwerp,
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Felizarta /ID# 141033
mi
from
Bakersfield, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Felizarta /ID# 141033
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Research & Education, Inc. /ID# 169591
mi
from
San Diego, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Research & Education, Inc. /ID# 169591
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
eStudySite San Diego /ID# 141040
mi
from
San Diego, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
eStudySite San Diego /ID# 141040
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
eStudySite San Diego /ID# 141047
mi
from
San Diego, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
eStudySite San Diego /ID# 141047
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
eStudySite San Diego /ID# 141048
mi
from
San Diego, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
eStudySite San Diego /ID# 141048
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Midway Immunology and Research /ID# 169477
mi
from
Fort Pierce, FL
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Midway Immunology and Research /ID# 169477
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Delta Research Partners, LLC /ID# 141028
mi
from
Bastrop, LA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Delta Research Partners, LLC /ID# 141028
mi
from
Bastrop, LA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Center, LLC /ID# 141024
mi
from
Shreveport, LA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Center, LLC /ID# 141024
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System /ID# 141039
mi
from
Detroit, MI
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System /ID# 141039
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Binghamton Gastroenterology /ID# 141026
mi
from
Binghamton, NY
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Binghamton Gastroenterology /ID# 141026
mi
from
Binghamton, NY
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Carolinas Center for Liver Dis /ID# 155390
mi
from
Huntersville, NC
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Carolinas Center for Liver Dis /ID# 155390
mi
from
Huntersville, NC
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Northwest Gastroenterology Cli /ID# 141036
mi
from
Portland, OR
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Northwest Gastroenterology Cli /ID# 141036
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Gastro One /ID# 169478
mi
from
Germantown, TN
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Gastro One /ID# 169478
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Quality Medical Research, PLLC /ID# 141042
mi
from
Nashville, TN
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Quality Medical Research, PLLC /ID# 141042
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
TX Clinical Research Institute /ID# 141037
mi
from
Arlington, TX
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
TX Clinical Research Institute /ID# 141037
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Inquest Clinical Research /ID# 141045
mi
from
Baytown, TX
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Inquest Clinical Research /ID# 141045
mi
from
Baytown, TX
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
TX Liver Inst, Americ Res Corp /ID# 136727
mi
from
San Antonio, TX
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
TX Liver Inst, Americ Res Corp /ID# 136727
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Bon Secours St. Mary's Hospita /ID# 165106
mi
from
Richmond, VA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Bon Secours St. Mary's Hospita /ID# 165106
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Digestive Health Specialists of the Southeast /ID# 136725
mi
from
Dothan, AL
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Digestive Health Specialists of the Southeast /ID# 136725
mi
from
Dothan, AL
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
Southern California Res. Ctr. /ID# 141799
mi
from
Coronado, CA
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
Southern California Res. Ctr. /ID# 141799
mi
from
Coronado, CA
Click here to add this to my saved trials
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated:  12/31/1969
St. Vincent's Hospital, Darlinghurst /ID# 155395
mi
from
Darlinghurst,
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Status: Enrolling
Updated: 12/31/1969
St. Vincent's Hospital, Darlinghurst /ID# 155395
mi
from
Darlinghurst,
Click here to add this to my saved trials
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center
mi
from
Irvine, CA
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center
mi
from
Irvine, CA
Click here to add this to my saved trials
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center
mi
from
Los Angeles, CA
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center
mi
from
San Diego, CA
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center
mi
from
San Marcos, CA
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center
mi
from
San Marcos, CA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated:  12/31/1969
Therafirst Medical Center
mi
from
Fort Lauderdale, FL
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated: 12/31/1969
Therafirst Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated:  12/31/1969
AIDS Healthcare Foundation
mi
from
Miami, FL
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated: 12/31/1969
AIDS Healthcare Foundation
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated:  12/31/1969
Orlando Immunology Center
mi
from
Orlando, FL
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)
Status: Enrolling
Updated: 12/31/1969
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials